metricas
covid
Buscar en
Revista Colombiana de Psiquiatría
Toda la web
Inicio Revista Colombiana de Psiquiatría Prevalencia y factores asociados a la no adherencia en el tratamiento farmacoló...
Journal Information
Vol. 40. Issue 1.
Pages 85-98 (March 2011)
Share
Share
Download PDF
More article options
Vol. 40. Issue 1.
Pages 85-98 (March 2011)
Artículos originales
Full text access
Prevalencia y factores asociados a la no adherencia en el tratamiento farmacológico de mantenimiento en adultos con trastorno afectivo bipolar*
Prevalence and Associated Factors of Non-Adherence to Treatment in Bipolar Disorder
Visits
1148
Elvia Elena Pardo Cely1,
Corresponding author
shelvis2004@yahoo.com

Correspondencia: Elvia Elena Pardo Cely, Carrera 26 No. 14A-38, Yopal, Casanare
, Marco Fierro2, Milciades Ibáñez Pinilla3
1 Residente de psiquiatría, Universidad del Rosario, Bogotá, Colombia
2 Médico psiquiatra. Profesor de psiquiatría, Departamento de Psiquiatría, Universidad del Rosario, Bogotá, Colombia
3 Estadístico, magíster en epidemiología. Docente de Investigación, Universidad del Rosario, Bogotá, Colombia
This item has received
Article information
Resumen
Introducción

Este artículo busca determinar la prevalencia y los factores asociados a la no adherencia en el tratamiento de mantenimiento de pacientes adultos con diagnóstico de trastorno afectivo bipolar.

Métodos

Estudio de corte transversal con 124 pacientes ambulatorios. Se evaluó la adherencia al tratamiento de mantenimiento con el cuestionario de Morisky-Green. Se usó, además, la escala de impresión clínica global modificada para el trastorno bipolar (CGI-BPM) y el test de Apgar familiar.

Resultados

La prevalencia de la no adherencia al tratamiento farmacológico de mantenimiento fue del 29,8%, y fue mayor para las mujeres (64,9%) que para los hombres (35,1%), si bien la diferencia no fue estadísticamente significativa (p=0,17). Los factores que de manera estadísticamente significativa se asociaron a la no adherencia fueron: mayor gravedad de la enfermedad (OR 1,9), antecedente de no adherencia (39%, p=0,001), menor insight (87%, RP 4,65), haberse sentido estigmatizado por padecer la enfermedad (50%, RP 6,2), el hábito de fumar (47,6%, p=0,048), mayor disfunción familiar, no contar con familiares que ayuden al paciente en la toma del medicamento (73%, p=0,001) y percepción negativa del médico tratante (100%, p=0,001).

Conclusiones

La prevalencia estuvo dentro del rango de otros estudios publicados. Los factores asociados a la no adherencia fueron: mayor gravedad de la enfermedad, sentirse estigmatizado, antecedentes de falta de adherencia, pobre insight, el hábito de fumar, disfunción familiar, no tener familiares que ayuden a tomar el medicamento y la percepción negativa del médico tratante.

Palabras clave:
Trastorno bipolar
adherencia farmacológica
cumplimiento del paciente
severidad de la enfermedad
estigma social
Abstract
Introduction

This study aims to determine the prevalence and factors associated with non-adherence in maintenance treatment of adult patients diagnosed with bipolar disorder.

Methods

Cross sectional study with 124 patients. Adherence to treatment was evaluated by the Morisky-Green Test. A structured questionnaire was applied. It included variables associated with demographics factors and factors related to the patient, illness, treatment, family, therapeutic relationship, and health system. The Global Impression Scale Modified for Bipolar Disorder (CGI-BPM) and Family Apgar were used as well.

Results

The prevalence of non-adherence to maintenance drug treatment was 29.8%. It was greater in women (64.9%) than men (35.1%), although this difference was not statistically significant (p = 0.17). The factors statistically significant associated with non-adherence factors were: Increased severity of the disease (OR 1.9), history of non-adherence (39% P=0,001), negative perception of the psychiatrist (100%, P=0.001), less insight (87%, RP4.65), greater stigma (50%, RP 6.2), having no family member to remind taking the drug (73%, P=0.001).

Conclusions

The prevalence was inside the range found in other studies. The statistically significant factors associated with non-adherence were: Severity of disease, history of non-compliance, stigma, no family support, poor insight, smoking habit, and negative perception of the psychiatrist.

Key words:
Bipolar disorder
medication adherence
patient compliance
severity of illness index
social stigma
Full text is only aviable in PDF
Referencias
[1]
GS Sachs, AJ Rush.
Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals?.
J Clin Psychiatry, 64 (2003), pp. 18-22
[2]
M Sajatovic.
Bipolar disorder: disease burden.
Am J Manag Care, 11 (2005), pp. S80-S84
[3]
KR Merikangas, HS Akiskal, J Angst, et al.
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.
Arch Gen Psychiatry, 64 (2007), pp. 543-552
[4]
RC Kessler, P Berglund, O Demler, et al.
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
Arch Gen Psychiatry, 62 (2005), pp. 593-602
[5]
S Pini, V de Queiroz, D Pagnin, et al.
Prevalence and burden of bipolar disorders in European countries.
Eur Neuropsychopharmacol, 15 (2005), pp. 425-434
[6]
JL Ayuso-Mateos.
Global burden of bipolar disorder in the year 2000, World Health Organization, (2000),
[7]
L Kleinman, A Lowin, E Flood, et al.
Costs of bipolar disorder.
Pharmacoeconomics, 21 (2003), pp. 601-622
[8]
D Chisholm, M van Ommeren, JL Ayuso-Mateos, et al.
Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.
Br J Psychiatry, 187 (2005), pp. 559-567
[9]
JR Geddes, S Burgess, K Hawton, et al.
Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.
Am J Psychiatry, 161 (2004), pp. 217-222
[10]
MJ Gitlin, J Swendsen, TL Heller, et al.
Relapse and impairment in bipolar disorder.
Am J Psychiatry, 152 (1995), pp. 1635-1640
[11]
M Sajatovic, M Valenstein, F Blow, et al.
Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder.
Psychiatr Serv, 58 (2007), pp. 855-863
[12]
R Lingam, J Scott.
Treatment non-adherence in affective disorders.
Acta Psychiatr Scand, 105 (2002), pp. 164-172
[13]
DA Perlick, RA Rosenheck, R Kaczynski, et al.
Medication non-adherence in bipolar disorder: a patient-centered review of research findings.
Clin Approaches Bipolar Disord, 3 (2004), pp. 56-64
[14]
L Tondo, G Isacsson, R Baldessarini.
Suicidal behaviour in bipolar disorder: risk and prevention.
CNS Drugs, 17 (2003), pp. 491-511
[15]
D Vieta.
Improving treatment adherence in bipolar disorder through psychoeducation.
J Clin Psychiatry, 66 (2005), pp. 24-29
[16]
F Colom, E Vieta, A Martínez-Arán, et al.
Clinical factors associated with treatment noncompliance in euthymic bipolar patient.
J Clin Psychiatry, 61 (2000), pp. 549-555
[17]
J Scott, M Pope.
Nonadherence with mood stabilizers: prevalence and predictors.
J Clin Psychiatry, 63 (2002), pp. 384-390
[18]
M Berk, L Berk, D Castle.
A collaborative approach to the treatment alliance in bipolar disorder.
Bipolar Disord, 6 (2004), pp. 504-518
[19]
F Colom, E Vieta.
Treatment adherence in bipolar patients.
Clin Approaches Bipolar Disord, 1 (2002), pp. 49-56
[20]
E Sabaté.
Adherencia a los tratamientos a largo plazo: pruebas para la acción, Organización Mundial de la Salud, (2004),
[21]
DI Velligan, PJ Weiden, Sajatovic, et al.
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
J Clin Psychiatry, 70 (2009), pp. 1-46
[22]
E Vieta, C Torrent, F Martínez-Arán, et al.
Escala sencilla de evaluación del curso del trastorno bipolar: CGI-BP-M.
Actas Esp Psiquiatr, 30 (2002), pp. 301-304
[23]
G Smilkstein.
The family APGAR: a proposal for a family function test and its use by physicians.
J Fam Pract, 6 (1978), pp. 1231-1239
[24]
G Smilkstein, C Ashworth, D Montano.
Validity and reliability of the Family APGAR as a test of family function.
J Fam Pract, 15 (1982), pp. 303-311
[25]
D Mejía Gómez.
Salud familiar para América Latina, Asociación Colombiana de Facultades de Medicina, (1991),
[26]
DE Morisky, LW Green, DM Levine.
Concurrent and predictive validity of a self-reported measure of medication adherence.
Med Care, 24 (1986), pp. 67-74
[27]
M Sajatovic, DI Velligan, PJ Weiden, et al.
Measurement of psychiatric treatment adherence.
J Psychosom Res, 69 (2010), pp. 591-599
[28]
J Scott, M Pope.
Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization.
Am J Psychiatry, 159 (2002), pp. 1927-1929
[29]
PE Keck Jr, SL McElroy, SM Strakowski, et al.
Factors associated with pharmacologic noncompliance in patients with mania.
J Clin Psychiatry, 57 (1996), pp. 292-297
[30]
PL Morselli, R Elgie.
GAMIAN-Europe. GAMIAN-Europe/BEAM survey I–global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders.
Bipolar Disord, 5 (2003), pp. 265-278
[31]
RD Weiss, SF Greenfield, LM Najavits, et al.
Medication compliance among patients with bipolar disorder and substance use disorder.
J Clin Psychiatry, 59 (1998), pp. 172-174
[32]
KR Jamison, RH Gerner, FK Goodwin.
Patient and physician attitudes towards lithium: relationship to compliance.
Arch Gen Psychiatry, 36 (1979), pp. 866-869
[33]
JM Danion, C Neunreuther, F Krieger-Finance, et al.
Compliance with long-term lithium treatment in major affective disorders.
Pharmacopsyachiatry, 20 (1987), pp. 230-231
[34]
J Aagaard, P Vestergaard, K Maarbjerg.
Adherence to lithium prophylaxis: II. Multivariate analysis of clinical, social, and psychological predictors of nonadherence.
Pharmacopsychiatry, 21 (1988), pp. 166-170
[35]
J Clatworthy, R Bowskill, T Rank, et al.
Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients' beliefs about the condition and its treatment.
Bipolar Disord, 9 (2007), pp. 656-664
[36]
PE Keck Jr, SL McElroy, SM Strakowsky, et al.
Compliance with maintenance treatment in bipolar disorder.
Psychopharmacol Bull, 33 (1997), pp. 87-91
[37]
J Adams, J Scott.
Predicting medication adherence in severe mental disorders.
Acta Psychiatr Scand, 101 (2000), pp. 119-124
[38]
SD Cochran, MJ Gitlin.
Attitudinal correlates of lithium compliance in bipolar affective disorders.
J Nerv Ment Dis, 176 (1988), pp. 457-464
[39]
JE Zeber, AL Miller, La Copeland, et al.
Medication adherence, ethnicity, and the influence of multiple psychosocial and financial barriers.
Adm Policy Ment Health, 38 (2011), pp. 86-95
[40]
JL Strauss, SL Johnson.
Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms.
Psychiatry Res, 145 (2006), pp. 215-223
[41]
RJ Baldessarini, R Perry, J Pike.
Factors associated with treatment nonadherence among US bipolar disorder patients.
Hum Psychopharmacol, 23 (2008), pp. 95-105
[42]
DJ Miklowitz, MJ Goldstein, KH Nuechterlein, et al.
Expressed emotion, affective style, lithium compliance, and relapse in recent onset mania.
Psychopharmacol Bull, 22 (1986), pp. 628-632
[43]
DA Perlick, RA Rosenheck, JF Clarkin, et al.
Impact of family burden and affective response on clinical outcome among patients with bipolar disorder.
Psychiatr Serv, 55 (2004), pp. 1029-1035

Este artículo es parte de la tesis Trastorno Afectivo Bipolar y adherencia Farmacológica, para optar al título como especialista en psiquiatría, Universidad del Rosario, 2011.

Conflictos de interés: Los autores manifiestan que no tienen conflictos de interés en este artículo.

Copyright © 2011. Asociación Colombiana de Psiquiatría
Article options